Acute Sore Throat Management Guidelines

Risk Stratification & Diagnostic Approach

• A validated clinical scoring system (Centor, McIsaac, or FeverPAIN) outperforms unaided clinician judgment and reduces unnecessary antibiotic prescriptions in patients with viral pharyngitis. 1
• Scoring criteria assign one point each for tonsillar exudate or enlargement, tender anterior cervical lymphadenopathy, fever > 38 °C, and absence of cough; age modifies the total (add 1 for 3–14 yr, 0 for 15–44 yr, subtract 1 for ≥ 45 yr). 1
• Patients scoring 0–2 have a < 10 % probability of Group A Streptococcus (GAS); they should receive symptomatic care only—no testing or antibiotics. 1
• Patients scoring 3 should undergo a rapid antigen detection test (RADT); a positive result warrants treatment, whereas a negative result in children/adolescents must be confirmed with throat culture. 1
• Patients scoring ≥ 4 should also receive RADT; a negative RADT does not require throat culture in adults, but is recommended in children and adolescents. 1
• A negative RADT in adults does not require follow‑up throat culture. 1
• Antibiotics are not indicated for patients with 0–2 Centor criteria because they have predominantly viral infection and derive no meaningful clinical benefit. 1
• The modest benefit of antibiotics in low‑risk patients is a reduction of sore‑throat duration by approximately 16 hours at day 3, which must be weighed against side‑effects and resistance. 1
• Suppurative complications are not a justification for antibiotics in low‑risk patients. 1
• In placebo groups, ≈ 82 % of patients are symptom‑free by one week without antibiotics. 1
• Clinical judgment alone should not be used to prescribe antibiotics; a validated scoring system must be applied. 1

Symptomatic Treatment

• Non‑steroidal anti‑inflammatory drugs (ibuprofen or naproxen) are first‑line for pain and fever; acetaminophen is an acceptable alternative. Aspirin must be avoided in children because of Reye syndrome risk. 2
• Systemic corticosteroids are not recommended; the modest ≈ 5‑hour pain‑duration reduction does not outweigh potential adverse effects. 2
• Zinc gluconate has no role in acute sore‑throat management. 2
• Encourage soft, cool foods and adequate hydration. 2

Antibiotic Therapy – First‑Line (Non‑Allergic)

• Penicillin V or amoxicillin for 10 days is the definitive first‑line regimen; no penicillin‑resistant GAS has been documented, and narrow‑spectrum agents minimize selection pressure. 2
• Amoxicillin 50 mg/kg once daily (max 1000 mg) for 10 days in children improves adherence. 2
• Amoxicillin 500 mg twice daily for 10 days in adults. 2
• Penicillin V 250 mg twice daily (children) or 500 mg 2–3 times daily (adults) for 10 days. 3
• Benzathine penicillin G single intramuscular injection is appropriate when oral adherence is uncertain or in patients at high risk for rheumatic fever. 2

Antibiotic Therapy – Penicillin‑Allergic Patients

• Non‑anaphylactic allergy (e.g., rash): first‑generation cephalosporins (cephalexin 20 mg/kg twice daily, max 500 mg/dose; or cefadroxil 30 mg/kg once daily, max 1 g) for 10 days are preferred, recognizing that ≈ 10 % of penicillin‑allergic individuals cross‑react. 2
• Anaphylactic allergy: Clindamycin 7 mg/kg three times daily (max 300 mg/dose) for 10 days is the most reliable alternative, with ~1 % GAS resistance in the United States. 2
• Azithromycin 12 mg/kg once daily (max 500 mg) for 5 days is an alternative, but macrolide resistance ranges 5–8 % (higher in some regions). 2
• Clarithromycin 7.5 mg/kg twice daily (max 250 mg/dose) for 10 days shares similar resistance concerns. 2
• In areas with high macrolide resistance, clindamycin is preferred over azithromycin or clarithromycin. 3

Critical Treatment Principles

• Complete the full 10‑day antibiotic course even if symptoms improve, to ensure pharyngeal eradication and prevent rheumatic fever. 2
• Antibiotics may be initiated 24–48 hours after presentation without increasing rheumatic fever risk; treatment remains effective when started up to 9 days after symptom onset. 3
• Clinical improvement typically occurs within 24–48 hours of starting antibiotics. 2
• Patients become non‑contagious after 24 hours of effective antibiotic therapy. 2

Agents to Avoid

• Tetracyclines, sulfonamides, and trimethoprim‑sulfamethoxazole do not eradicate GAS and should not be used. 2
• Ciprofloxacin and older fluoroquinolones are ineffective against GAS and should be avoided. 2

Situations Where Antibiotics Should NOT Be Used

• In patients with 0–2 Centor criteria (low‑risk), antibiotics provide no meaningful benefit and contribute to resistance and adverse effects. 1

Follow‑Up & Red‑Flag Management

• Symptoms usually improve within 24–48 hours of antibiotic initiation and resolve completely within 3–5 days. 2
• Children may return to school/day‑care after 24 hours of antibiotics and being fever‑free for 24 hours without antipyretics. 2
• Re‑evaluation is warranted if symptoms worsen or fail to improve within 48–72 hours of therapy, suggesting treatment failure or complication. 2
• Immediate medical attention is required for difficulty breathing, severe dysphagia, neck stiffness, or markedly deteriorating appearance. 2
• New or worsening symptoms after initial response may indicate suppurative complications (e.g., peritonsillar abscess). 2
• Routine post‑treatment throat cultures or RADTs are unnecessary after uneventful recovery; testing should be reserved for special circumstances (e.g., prior rheumatic fever, persistent symptoms). 2

Special Populations

• Children < 3 years: Routine microbiologic testing is not recommended because acute rheumatic fever is rare and classic streptococcal pharyngitis uncommon; testing only when specific risk factors (e.g., older sibling with confirmed GAS) are present. 2
• Pregnant and immunocompromised patients: May require lower thresholds for testing and treatment, but specific recommendations are not detailed in the cited sources.